{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-26-000041","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2026-05-14T20:06:45+00:00","discovered_at":"2026-05-14T20:09:00.303422+00:00","generated_at":"2026-05-14T21:00:01.210748+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AEON Biopharma reports Q1 cash $6.2M; FDA supports ABP-450 biosimilar plan; debt cut >90%","bullets":["FDA BPD Type 2a meeting deemed AEON's analytical similarity strategy reasonable for 351(k) pathway.","Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by >90%.","Appointed John Bencich as CFO, bringing 25+ years of corporate and capital markets experience.","Cash and cash equivalents $6.2M at March 31, plus $0.9M April ATM; funds operations into Q3 2026.","Plans BPD Type 2b meeting in H2 2026 to discuss remaining biosimilar development program."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-26-000041","json":"https://secwatch.observer/filing/0001837607-26-000041.json","markdown":"https://secwatch.observer/filing/0001837607-26-000041.md","text":"https://secwatch.observer/filing/0001837607-26-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/0001837607-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/aeon-20260514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:00:01.210748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc698460af96fffd507af50301f9e628c04d1bf6","claim":"AEON Biopharma, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 14, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/0001837607-26-000041-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}